Guk-Hyun Hwang
Vorstandsvorsitzender bei BELLEVUE LIFE SCIENCES ACQUISITION CORP.
Vermögen: 14 Mio $ am 31.05.2024
Profil
Mr. Guk-Hyun Hwang is a Co-Chairman at Vaximm AG, a Chief Executive Officer & Director at BCM Europe AG, a Chief Executive Officer & Director at Bellevue Life Sciences Acquisition Corp., a Chairman & Chief Executive Officer at OSR Holdings Co., Ltd.
and a Managing Partner at Bellevue Capital Management LLC.
He is on the Board of Directors at BCM Europe AG and Bellevue Life Sciences Acquisition Corp.
He received his undergraduate degree from Korea University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
18.04.2024 | 1 320 500 ( 23,48% ) | 14 Mio $ | 31.05.2024 |
Aktive Positionen von Guk-Hyun Hwang
Unternehmen | Position | Beginn |
---|---|---|
BELLEVUE LIFE SCIENCES ACQUISITION CORP. | Vorstandsvorsitzender | 01.03.2020 |
Bellevue Capital Management LLC | Gründer | 01.08.2012 |
OSR Holdings Co., Ltd.
OSR Holdings Co., Ltd. Pharmaceuticals: MajorHealth Technology OSR Holdings Co., Ltd. is a South Korean healthcare company that develops and licenses innovative biomedical therapies based on proprietary platform technologies to address unmet medical needs. The private company is based in an undisclosed location. The company wholly-owns three operating subsidiaries focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases. OSR Holdings signed a letter of intent to acquire Landmark Bioventures AG, a Swiss company that operates through four different biotech ventures with therapeutic focuses on oncology and immunology. The company was founded in 2019, and the CEO is Sean Chung. | Vorstandsvorsitzender | 01.07.2019 |
BCM Europe AG
BCM Europe AG Investment ManagersFinance BCM Europe AG provides investment and financial advisory services. The private company is based in Zug, Switzerland and has subsidiaries in Switzerland. Guk-Hyun Hwang has been the CEO of the Swiss company since 2020. | Vorstandsvorsitzender | 01.03.2020 |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Vorsitzender | 01.11.2022 |
Ausbildung von Guk-Hyun Hwang
Korea University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
BELLEVUE LIFE SCIENCES ACQUISITION CORP. | Finance |
Private Unternehmen | 4 |
---|---|
Bellevue Capital Management LLC | |
OSR Holdings Co., Ltd.
OSR Holdings Co., Ltd. Pharmaceuticals: MajorHealth Technology OSR Holdings Co., Ltd. is a South Korean healthcare company that develops and licenses innovative biomedical therapies based on proprietary platform technologies to address unmet medical needs. The private company is based in an undisclosed location. The company wholly-owns three operating subsidiaries focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases. OSR Holdings signed a letter of intent to acquire Landmark Bioventures AG, a Swiss company that operates through four different biotech ventures with therapeutic focuses on oncology and immunology. The company was founded in 2019, and the CEO is Sean Chung. | Health Technology |
BCM Europe AG
BCM Europe AG Investment ManagersFinance BCM Europe AG provides investment and financial advisory services. The private company is based in Zug, Switzerland and has subsidiaries in Switzerland. Guk-Hyun Hwang has been the CEO of the Swiss company since 2020. | Finance |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |